Dexcom delivered robust financial performance in Q3 2025, with worldwide revenue increasing by 22% year-over-year to $1.209 billion. The company also saw a substantial rise in GAAP operating income by 480 basis points and non-GAAP operating income by 130 basis points compared to the prior year.
Worldwide revenue grew 22% year-over-year to $1.209 billion.
GAAP operating income reached $242.5 million, representing 20.1% of revenue, a 480 basis point increase.
Non-GAAP operating income was $272.9 million, or 22.6% of reported revenue, up 130 basis points.
U.S. revenue increased by 21% and international revenue grew by 22% on a reported basis year-over-year.
Dexcom is raising its fiscal year 2025 guidance for Revenue and updating guidance for Non-GAAP Gross Profit Margin, Non-GAAP Operating Margin, and Adjusted EBITDA Margin.
Visualization of income flow from segment revenue to net income